NASDAQ:APLS - Apellis Pharmaceuticals Stock Price, Forecast & News

Apellis Pharmaceuticals trades on the NASDAQ under the ticker symbol "APLS."

Apellis Pharmaceuticals Inc (NASDAQ:APLS) released its earnings results on Tuesday, November, 5th. The company reported ($1.10) earnings per share for the quarter, missing the Zacks' consensus estimate of ($1.01) by $0.09. View Apellis Pharmaceuticals' Earnings History.

10 brokers have issued 1 year target prices for Apellis Pharmaceuticals' stock. Their forecasts range from $23.00 to $80.00. On average, they anticipate Apellis Pharmaceuticals' share price to reach $46.09 in the next year. This suggests a possible upside of 37.2% from the stock's current price. View Analyst Price Targets for Apellis Pharmaceuticals.

10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Apellis Pharmaceuticals in the last year. There are currently 1 sell rating, 3 hold ratings and 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Apellis Pharmaceuticals.

Media coverage about APLS stock has trended very negative on Friday, according to InfoTrie. InfoTrie identifies negative and positive news coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Apellis Pharmaceuticals earned a daily sentiment score of -3.2 on InfoTrie's scale. They also assigned news articles about the company a news buzz of 4.0 out of 10, indicating that recent news coverage is somewhat unlikely to have an effect on the company's share price in the next few days. View News Stories for Apellis Pharmaceuticals.

Apellis Pharmaceuticals saw a increase in short interest during the month of January. As of January 31st, there was short interest totalling 6,670,000 shares, an increase of 22.4% from the January 15th total of 5,450,000 shares. Based on an average daily volume of 1,370,000 shares, the days-to-cover ratio is presently 4.9 days. Approximately 12.6% of the shares of the company are sold short. View Apellis Pharmaceuticals' Current Options Chain.

Some companies that are related to Apellis Pharmaceuticals include Mylan (MYL), Beigene (BGNE), Sarepta Therapeutics (SRPT), Perrigo (PRGO), Bausch Health Companies (BHC), Ionis Pharmaceuticals (IONS), Catalent (CTLT), Jazz Pharmaceuticals (JAZZ), Dr.Reddy's Laboratories (RDY), The Medicines (MDCO), Horizon Therapeutics (HZNP), ACADIA Pharmaceuticals (ACAD), Ascendis Pharma A/S (ASND), Reata Pharmaceuticals (RETA) and Amarin (AMRN).

Based on aggregate information from My MarketBeat watchlists, some companies that other Apellis Pharmaceuticals investors own include Viking Therapeutics (VKTX), Corbus Pharmaceuticals (CRBP), Fate Therapeutics (FATE), Sorrento Therapeutics (SRNE), KemPharm (KMPH), Aurinia Pharmaceuticals (AUPH), Anavex Life Sciences (AVXL), Axsome Therapeutics (AXSM), ChemoCentryx (CCXI) and Exelixis (EXEL).

(APLS) raised $150 million in an IPO on Thursday, November 9th 2017. The company issued 10,700,000 shares at $13.00-$15.00 per share. Citigroup, J.P. Morgan and Evercore ISI acted as the underwriters for the IPO.

Apellis Pharmaceuticals' stock is owned by many different of retail and institutional investors. Top institutional investors include Victory Capital Management Inc. (3.10%), State Street Corp (3.07%), Victory Capital Management Inc. (2.90%), FIL Ltd (1.86%), Barclays PLC (1.55%) and Jennison Associates LLC (1.48%). Company insiders that own Apellis Pharmaceuticals stock include Cedric Francois, David O Watson, Lukas Scheibler, Morningside Venture Investment, Pascal Deschatelets and Timothy Eugene Sullivan. View Institutional Ownership Trends for Apellis Pharmaceuticals.

APLS stock was sold by a variety of institutional investors in the last quarter, including Sectoral Asset Management Inc, Fiduciary Trust Co., Jane Street Group LLC, SG Americas Securities LLC, Candriam Luxembourg S.C.A., Pictet Asset Management Ltd., Baird Financial Group Inc. and Prudential Financial Inc.. Company insiders that have sold Apellis Pharmaceuticals company stock in the last year include Cedric Francois and Pascal Deschatelets. View Insider Buying and Selling for Apellis Pharmaceuticals.

APLS stock was purchased by a variety of institutional investors in the last quarter, including Barclays PLC, State Street Corp, Victory Capital Management Inc., Farallon Capital Management LLC, Victory Capital Management Inc., FIL Ltd, FMR LLC and Bank of Montreal Can. Company insiders that have bought Apellis Pharmaceuticals stock in the last two years include Lukas Scheibler, Morningside Venture Investment and Timothy Eugene Sullivan. View Insider Buying and Selling for Apellis Pharmaceuticals.

Shares of APLS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of APLS stock can currently be purchased for approximately $33.60.

Apellis Pharmaceuticals has a market capitalization of $2.52 billion. The company earns $-127,500,000.00 in net income (profit) each year or ($2.34) on an earnings per share basis. Apellis Pharmaceuticals employs 87 workers across the globe.View Additional Information About Apellis Pharmaceuticals.

The official website for Apellis Pharmaceuticals is http://www.apellis.com/.

Apellis Pharmaceuticals' mailing address is 6400 WESTWIND WAY SUITE A, CRESTWOOD KY, 40014. The company can be reached via phone at 502-241-4114 or via email at [email protected]